$-0.58 EPS Expected for Mersana Therapeutics, Inc. (MRSN)

August 9, 2018 - By Jason Dias

Analysts expect Mersana Therapeutics, Inc. (NASDAQ:MRSN) to report $-0.58 EPS on August, 10.They anticipate $5.75 EPS change or 90.84 % from last quarter’s $-6.33 EPS. After having $-0.54 EPS previously, Mersana Therapeutics, Inc.’s analysts see 7.41 % EPS growth. The stock increased 0.80% or $0.1 during the last trading session, reaching $12.59. About 91,364 shares traded. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $288.34 million. The firm develops immune conjugate therapies to create drugs that enhance patients?? lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

More notable recent Mersana Therapeutics, Inc. (NASDAQ:MRSN) news were published by: Streetinsider.com which released: “Pre-Open Stock Movers 07/19: (TTS) (DWCH) (NDLS) Higher; (MRSN) (EBAY) (RPM) Lower (more…)” on July 19, 2018, also 247Wallst.com with their article: “Mersana Cries for Mercy” published on July 19, 2018, Nasdaq.com published: “Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2018 Financial Results and Business …” on July 21, 2018. More interesting news about Mersana Therapeutics, Inc. (NASDAQ:MRSN) were released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Open Lower; Philip Morris Profit Beats Views” published on July 19, 2018 as well as Schaeffersresearch.com‘s news article titled: “NHTC, AA, MRSN Stocks Suffer Nasty Pullbacks” with publication date: July 19, 2018.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.